Resistant hypertension, secondary hypertension, and hypertensive crises

Cardiology Clinics

Volumn 20, Issue 2, 2002, Pages 281-289

  Hall, W Dallas ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRILAT; ESMOLOL; FENOLDOPAM; GLYCERYL TRINITRATE; LABETALOL; LOOP DIURETIC AGENT; METIROSINE; NICARDIPINE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTETATE TECHNETIUM TC 99M; PHENOXYBENZAMINE; PHENTOLAMINE; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL;

ANGIOPLASTY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CUSHING SYNDROME; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HEART FAILURE; HEART INFARCTION; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY SCINTISCANNING; PATIENT COMPLIANCE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW; SLEEP APNEA SYNDROME; STROKE; TREATMENT INDICATION; DRUG RESISTANCE; HOSPITALIZATION; HUMAN; RECURRENT DISEASE; RISK FACTOR; TREATMENT FAILURE;

DRUG RESISTANCE; HUMANS; HYPERTENSION; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 0035987997     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(01)00004-2     Document Type: Article

References (61)

1. Resistant hypertension in a tertiary care clinic
2. Contemporary management of refractory hypertension
3. Refractory hypertension
4. The multilevel compliance challenge: Recommendations for a call to action. A statement for healthcare professionals
5. Problems of treatment compliance and polypharmacy
6. Nonsteroidal anti-inflammatory drugs and hypertension
7. Interactions of antihypertensive drugs with anti-inflammatory drugs
8. Refractory hypertension
9. Plasma volume in resistant hypertension: Guide to pathophysiology and therapy
10. Physiologic tailoring of therapy for resistant hypertension: 20 Years' experience with stimulated renin profiling
11. On chronic Bright's disease, and its essential symptoms
12. Bestehen beziehungen zwischen chromaffinem system und der chronischen hypertonie des menschen?
13. When to suspect secondary hypertension
14. Renal revascularization for recurrent pulmonary edema and renovascular hypertension
15. What is critical renal artery stenosis? Implications for treatment
16. Diagnosis of renovascular hypertension: An overview
17. Renovascular hypertension: Diagnosis and treatment
18. Renal revascularization using percutaneous balloon angioplasty for fibromuscular dysplasia and atherosclerotic disease
19. Treatment of ostial renal-artery stenoses with vascular endoprosthesis after unsuccessful balloon angioplasty
20. Effect of renalartery stenting on progression of renovascular renal failure
21. Atheroembolic renal disease
22. Cholesterol emboli: A common cause of renal failure
23. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis
24. Hypertension in autosomal-dominant polycystic kidney disease: Early occurrence and unique aspects
25. Prognostic value of serum creatinine and effect of treatment on hypertension and renal function: Results from the hypertension detection and follow-up program
26. Preserving renal function in adults with hypertension and diabetes: A consensus report
27. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial
28. Renoprotective effects of antihypertensive drugs
29. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study
30. Prospective study of the association between sleep-disordered breathing and hypertension
31. Using the Berlin questionnaire to identify patients at risk for the sleep apnea syndrome
32. Cost utility of three approaches to the diagnosis of sleep apnea: Polysomnography, home testing, and empirical therap
33. Primary aldosteronism
34. Diagnosis and treatment of primary aldosteronism
35. Primary aldosteronism
36. Primary aldosteronism
37. Medical management of aldosterone-producing adenomas
38. Cushing's syndrome
39. Diagnosis and management of Cushing's syndrome
40. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma
41. Changes in clinical features and long-term prognosis in patients with pheochromocytoma
42. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
43. Hypertensive urgencies and emergencies. Prevalence and clinical presentation
44. Hypertensive crisis
45. The diagnosis and management of hypertensive crises
46. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudo-emergencies?
47. Comparative tolerability profile of hypertensive crisis treatments
48. Hypertensive crises
49. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension
50. Hypertensive emergencies
51. Intravenous nicardipine for the treatment of severe hypertension
52. Haemodynamic changes during minimally invasive coronary artery bypass surgery using high-dose esmolol
53. Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension
54. Esmolol: A titratable short-acting intravenous beta blocker for acute critical care settings
55. Esmolol: A review of its therapeutic efficacy and pharmacokinetic characteristics
56. The safety and effectiveness of esmolol in the perioperative period in patients undergoing abdominal aortic surgery
57. Fenoldopam: A new parenteral antihypertensive. Consensus roundtable on the management of perioperative hypertension and hypertensive crises
58. Prolonged fenoldopam infusions in patients with mild to moderate hypertension
59. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension